Pharma BD Deal Intelligence
Deal direction as stated is factually backwards; the real 2018 transaction was GSK divesting its rare-disease gene therapy portfolio TO Orchard Therapeutics for a 19.9% equity stake + royalties/milestones — and it produced a genuine mixed outcome (one discontinued product, one now-approved blockbuster-priced therapy, eventual buyout of Orchard by Kyowa Kirin).
Full analysis, sources & comparables →Orchard licensed GSK's rare-disease gene therapy portfolio in a deal that took the company from two clinical-stage assets to five plus a commercial asset and…
The whirlwind rise of Orchard Therapeutics — six weeks after GSK announced rare-disease exit, Orchard absorbed the portfolio and raised $150M Series C, an…
Orchard followed the GSK buyout with FDA approval of Lenmeldy for metachromatic leukodystrophy in March 2024 — six years post-deal, validating the portfolio…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
GSK transferred its rare disease gene therapy portfolio to Orchard Therapeutics in April 2018. In return GSK received a 19.9% equity stake plus board seat, royalties on Strimvelis (first approved ex vivo lentiviral gene therapy, for ADA-SCID), and commercial milestone payments. Portfolio includes OTL-101 (ADA-SCID), OTL-200 (MLD), OTL-300 (TDT), plus three preclinical programs from Telethon/San Raffaele. Strategically notable as one of the largest gene therapy portfolio carve-outs to date.
Deal direction as stated is factually backwards; the real 2018 transaction was GSK divesting its rare-disease gene therapy portfolio TO Orchard Therapeutics for a 19.9% equity stake + royalties/milestones — and it produced a genuine mixed outcome (one discontinued product, one now-approved blockbuster-priced therapy, eventual buyout of Orchard by Kyowa Kirin).
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Orchard Therapeutics Limited / GlaxoSmithKline plc (this deal) | 2018 | — | 60 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2018 deals · Hematology deals